Ovarian Cancer | Current Treatment: Physician Insights | US | 2022
The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca / Merck & Co.’s Lynparza, GlaxoSmithKline’s Zejula, and Clovis Oncology’s Rubraca are altering physicians’ prescribing habits and creating new dynamics in treatment sequencing. Notably, the label expansions of existing therapies to the first-line maintenance setting (e.g., Lynparza plus bevacizumab maintenance for HRD-positive patients, Zejula maintenance irrespective of BRCA or HRD status) are having an impact on prescribing decisions.
QUESTIONS ANSWERED
- What are the key prescribing influences on physicians’ choice of first-line maintenance treatment (e.g., Lynparza plus bevacizumab versus Zejula) for advanced-stage ovarian cancer?
- What is the patient share of key therapies used to treat advanced-stage (first- to fourth-line therapy) ovarian cancer
- What are the key drivers of and obstacles to the use of bevacizumab and PARP inhibitors for advanced-stage ovarian cancer?
- How do drug-treatment rates vary between key ovarian cancer patient populations, according to stage of disease and line of therapy?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 102 medical oncologists in the United States fielded in March 2022
Key drugs: Bevacizumab, Lynparza, Zejula, and Rubraca
